KENILWORTH, N.J., May 30 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) announced today that about 80 posters, poster
discussions, and oral presentations from about 60 clinical studies relating
to its growing oncology franchise will be presented at the upcoming 44th
Annual Meeting of the American Society of Clinical Oncology (ASCO) in
Chicago, May 30 - June 3. Data will be presented on TEMODAR(R)
(temozolomide) Capsules, CAELYX(R) (pegylated liposomal doxorubicin
hydrochloride), INTRON(R) A (Interferon alfa-2b, recombinant) for Injection
and peginterferon alfa-2b, as well as the company's investigational
oncology compounds including SCH 727965.
-- TEMODAR(R): Twenty-eight abstracts will be presented, including 10
poster discussions and eight oral presentations.
-- CAELYX(R): Eleven abstracts will be presented, including two poster
discussions and two oral presentations.
-- INTRON(R) A and peginterferon alfa-2b: Data will be featured in more
than 10 abstracts, including five poster discussions and five oral
Please see important full U.S. Prescribing Information, and the Medication Guides for INTRON(R) A and peginterferon alfa-2b at http://www.schering-plough.com.
Schering-Plough Corp. has exclusive ex-U.S. marketing rights to CAELYX(R), except in Japan and Israel, through a distribution agreement with ALZA, a wholly owned subsidiary of Johnson & Johnson, New Brunswick, N.J., USA. The product is marketed in the United States under the tradename DOXIL(R) by Ortho Biotech Products, L.P. Full EU Prescribing Information may be accessed at http://www.emea.europa.eu/humandocs/PDFs/EPAR/Caelyx/H-089-PI-en.pdf.
Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.
SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the potential market and the clinical development of its oncology portfolio. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part I, Item 1A, "Risk Factors" in Schering-Plough's 2008 Q1 10-Q.
|SOURCE Schering-Plough Corporation|
Copyright©2008 PR Newswire.
All rights reserved